Research guide · Published July 22, 2026 · Sources checked July 22, 2026
GLP catalog shorthand and literature identifiers explained
The labels GLP-1, GLP-2, and GLP-3 may appear in catalog history as short product-family labels. They are not complete chemical identifiers and should not replace full material names, CAS registry numbers, or lot records.
Short answer
In this catalog, GLP-1 / Sema refers to semaglutide, GLP-2 / Tirzep refers to tirzepatide, and GLP-3 / Reta refers to retatrutide. The full name and material-specific documentation control when identifying a supplied batch.
Evidence boundary: This is a nomenclature guide. It provides no preparation, administration, dosing, or human-use guidance. Catalog materials are supplied only for lawful nonclinical research and are not for human or animal use.
Comparison at a glance
| Catalog shorthand | Full material name | Literature identifier | CAS Registry Number |
|---|---|---|---|
| GLP-1 / Sema | Semaglutide | Semaglutide | 910463-68-2 |
| GLP-2 / Tirzep | Tirzepatide | LY3298176 | 2023788-19-2 |
| GLP-3 / Reta | Retatrutide | LY3437943 | 2381089-83-2 |
| Lot identifier | Material-specific | Not assigned by a paper title | Not a substitute for the lot number |
How to interpret the comparison
Use shorthand only for catalog navigation. Purchase records, labels, analytical reports, and laboratory records should use the full material name and matching lot identifier.
A CAS registry number helps disambiguate a substance record, but lot-specific verification still depends on the sample identifier, method, and reported analytical results.
Primary sources
- Lau et al., Journal of Medicinal Chemistry (2015) — Primary literature describing the molecular design of semaglutide study material. DOI: 10.1021/acs.jmedchem.5b00726
- Coskun et al., Molecular Metabolism (2018) — Primary literature identifying tirzepatide as LY3298176. DOI: 10.1016/j.molmet.2018.09.009
- Coskun et al., Cell Metabolism (2022) — Primary literature identifying retatrutide as LY3437943. DOI: 10.1016/j.cmet.2022.07.013
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.